Shenzhen Pregene Biopharma Co., Ltd. (874090) is a national high-tech enterprise with the mission of “Developing urgently needed cell and gene therapy drugs for clinical treatment”. Its product pipelines include CAR-T and CAR-NK drugs with multiple targets, with indications covering multiple therapeutic fields such as hematological tumors, solid tumors, and autoimmune diseases. Pregene has always adhered to the development strategies and paths of independent research and development (R&D) and technology platformization, platform productization, product commercialization and commercial internationalization. As an innovative pharmaceutical company in the industry that currently takes the lead in realizing the global multi-regional authorization of CAR-T cell agents, it has established a complete core technology platform for cell drug R&D and industrialization and is committed to becoming an international first-class cell and gene therapy drug company.